All In Biotech

NDA 209963 · Lxo Ireland

Goprelto

Cocaine Hydrochloride · Nasal

Last checked: Nov 20, 2026Latest source record: Jul 18, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Dec 14, 2017

Approved uses

1

Original approval plus efficacy supplements

Registered trials

415

35 Phase 3, 16 recruiting

FAERS reports

381

370 serious, 245 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: ABUSE AND DEPENDENCE CNS stimulants, including cocaine hydrochloride, have a high potential for abuse and dependence [see Warning and Precautions (5.1) . ] WARNING: ABUSE AND DEPENDENCE See full prescribing information for complete boxed warning. CNS stimulants, including cocaine hydrochloride, have a high potential for abuse and dependence. (5.1)

What it is approved for

From the label in effect Nov 6, 2024.

GOPRELTO (cocaine hydrochloride) nasal solution is indicated for the induction of local anesthesia of the mucous membranes when performing diagnostic procedures and surgeries on or through the nasal cavities in adults. GOPRELTO (cocaine hydrochloride) nasal solution is an ester local anesthetic indicated for the induction of local anesthesia of the mucous membranes when performing diagnostic procedures and surgeries on or through the nasal cavities in adults. ( 1 )

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 14, 2017 Original approval · Type 5 - New Formulation or New Manufacturer LetterReviewLabel
1 products under this application
  • GOPRELTO · COCAINE HYDROCHLORIDE 4% · SOLUTION, NASAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Cocaine" as an intervention, any sponsor and status, largest first.

All 415 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • completed suicide95
  • cardiac arrest91
  • respiratory arrest86
  • drug abuse52
  • toxicity to various agents47
  • poisoning deliberate38
  • product use issue38
  • death29
  • suicidal ideation23
  • drug dependence21
  • suspected suicide20
  • intentional product misuse19

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041
20051
20061
20071
20083
20093
20112
20121
20152
20162
201713
201819
201930
202057
202149
202247
202347
202436
202554
202612

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,398 on PubMed

Sponsor: Lxo Ireland

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.